-+ 0.00%
-+ 0.00%
-+ 0.00%
Hengrui Pharmaceutical (01276): Some products are included in the 2026 national medical insurance catalogue
Share
Listen to the news

Zhitong Finance App News, Hengrui Pharmaceutical (01276) announced that some of the company's products will be included in the 2026 national health insurance catalogue.

Through medical insurance negotiations, zemetostat tablets, ruzinolide tablets, and hengagliptin regagliptin metformin sustained-release tablets (II) were included in the national medical insurance catalogue for the first time; new indications for injectable Ruikon trastuzumab were successfully included in the national medical insurance catalogue; successful renewal of darucilidine hydroxyesulfonate tablets and new indications included in the national medical insurance catalogue; proline henglizumab tablets, reviluramide tablets, tejillidine fumarate injections, orteconazole capsules, and henglixine metformin sustained-release tablets (I)/(II), injectable carelizumab, and pregabalin sustained-release tablets were successfully renewed and retained in the national medical insurance catalogue.


Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending